Subsequently, mutations in genes other than JAK2 have been described: MPL mutations, with a frequency ranging from 3 to 8% (15, 16), and, more recently, somatically acquired mutations in the calreticulin (CALR) gene, reported in about 25–35% of all ET cases (17, 18). Here, JAK2 is linked to essential thrombocythemia.